Oral Miltefosine for Indian Visceral Leishmaniasis | Zendy

Shyam Sundar | Zendy; T. K. Jha | Zendy; C.P. Thakur | Zendy; Juergen Engel | Zendy; H. Sindermann | Zendy; Christina Fischer | Zendy; Klaus Junge | Zendy; A.D.M. Bryceson | Zendy; Jonathan Berman | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Oral Miltefosine for Indian Visceral Leishmaniasis

Author(s) -

Shyam Sundar,

T. K. Jha,

C.P. Thakur,

Juergen Engel,

H. Sindermann,

Christina Fischer,

Klaus Junge,

A.D.M. Bryceson,

Jonathan Berman

Publication year - 2002

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa021556

Subject(s) - miltefosine , medicine , visceral leishmaniasis , leishmaniasis , amphotericin b , surgery , gastroenterology , sodium stibogluconate , vomiting , dermatology , immunology , antifungal

There are 500,000 cases per year of visceral leishmaniasis, which occurs primarily in the Indian subcontinent. Almost all untreated patients die, and all the effective agents have been parenteral. Miltefosine is an oral agent that has been shown in small numbers of patients to have a favorable therapeutic index for Indian visceral leishmaniasis. We performed a clinical trial in India comparing miltefosine with the most effective standard treatment, amphotericin B.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research